TP53 and hepatocellular carcinoma: In the hepatocellular carcinoma HA22T cells, it inhibited cell viability, reduced cellular proliferative proteins, and induced cell cycle arrest in the G2/M phase through p53 activation and inhibition of the PI3K-Akt-mouse double minute 2 homolog (MDM2) signaling pathway.